Effects of Oral Drugs on Coronary Microvascular Function in Patients Without Significant Stenosis of Epicardial Coronary Arteries: A Systematic Review and Meta-Analysis of Coronary Flow Reserve

Frontiers in Cardiovascular Medicine
Jingwen YongXiantao Song

Abstract

Objective: This study aims to investigate the impact of cardiovascular medications on the coronary flow reserve (CFR) in patients without obstructive coronary artery disease (CAD). Methods: We searched PubMed, EMBASE, and Cochrane databases from inception to 15 November 2019. Studies were included if they reported CFR from baseline to follow-up after oral drug therapy of patients without obstructive CAD. Data was pooled using random-effects modeling. The primary outcome was change in CFR from baseline to follow-up after oral drug therapy. Results: A total of 46 studies including 845 subjects were included in this study. Relative to baseline, the CFR was improved by angiotensin-converting enzymes (ACEIs), aldosterone receptor antagonists (ARBs) [standard mean difference (SMD): 1.12; 95% CI: 0.77-1.47], and statins treatments (SMD: 0.61; 95%CI: 0.36-0.85). Six to 12 months of calcium channel blocker (CCB) treatments improved CFR (SMD: 1.04; 95% CI: 0.51-1.58). Beta-blocker (SMD: 0.24; 95% CI: -0.39-0.88) and ranolazine treatment (SMD: 0.31; 95% CI: -0.39-1.01) were not associated with improved CFR. Conclusions: Therapy with ACEIs, ARBs, and statins was associated with improved CFR in patients with confirmed or suspicious CMD. CCB...Continue Reading

References

Jan 1, 1990·Circulation·F CreaA Maseri
Sep 3, 2002·Journal of the American College of Cardiology·Olakunle O AkinboboyeSteven R Bergmann
Nov 14, 2003·European Heart Journal·Meral KayikciogluInan Soydan
May 29, 2004·The American Journal of Cardiology·Kohei FujimotoJunichi Yoshikawa
Oct 14, 2004·Journal of Hypertension·Maurizio GalderisiGiovanni de Simone
Sep 8, 2006·Journal of Hypertension·Juán-Pablo TomásAlberto García-Lledó
Jan 30, 2007·Journal of Magnetic Resonance Imaging : JMRI·Silvia S BlemkerScott L Delp
Sep 7, 2007·Clinical Cardiology·Mustafa CaliskanHaldun Muderrisoglu
Oct 6, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Fumihiko KamezakiYutaka Otsuji
Mar 29, 2008·Drugs·Maurizio Galderisi, Arcangelo D'Errico
Oct 16, 2008·Current Vascular Pharmacology·Michel R HoenigFrank W Sellke
Sep 8, 2009·Therapeutic Advances in Cardiovascular Disease·Yilmaz GunesHakki Simsek
Oct 19, 2011·Circulation·Venkatesh L MurthyMarcelo F Di Carli
Feb 22, 2012·Coronary Artery Disease·Kenji IinoHiroshi Ito
Aug 23, 2012·Heart, Lung & Circulation·Simon Stewart
Dec 12, 2012·Journal of Cardiovascular Medicine·Gaetano A LanzaUNKNOWN Gruppo di Studio di Fisiopatologia Coronarica e Microcircolazione, Società Italiana di Cardiologia
Dec 19, 2012·Expert Review of Cardiovascular Therapy·Claire S Duvernoy
Apr 6, 2013·The American Journal of Cardiology·Angelo VillanoFilippo Crea
Nov 22, 2013·Coronary Artery Disease·Xinling ZhangJianmin Yang
Nov 29, 2013·Journal of Human Hypertension·K StamatelopoulosS Toumanidis
Dec 25, 2013·European Heart Journal·Filippo CreaCathleen Noel Bairey Merz

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques
pharmacotherapy
coronary artery bypass

Software Mentioned

Stata
Review Manager

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.